Salubris(SZ:002294) 智通财经网·2026-02-12 23:13Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. is a pioneer in the treatment of cardiovascular-renal-metabolic diseases in China, ranking as the second-largest pharmaceutical company in the cardiovascular innovation drug sector by revenue in 2024 [3] - The company has a robust pipeline of innovative drugs targeting unmet medical needs in the cardiovascular-renal-metabolic syndrome area, which is characterized by the pathological interaction between metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system [3][8] Product Portfolio - Xinlitai has six innovative drugs, including Xinlitai (approved in 2013), Fuli Tian (expected approval in 2024), Xinlitin (expected approval in 2024), Xinchao Tuo (expected approval in 2025), Fuli An (expected approval in 2025), and Ennaloro (approved in early 2023 with expanded indications expected in 2025) [4] - The sales revenue from innovative drugs is projected to increase from 30.1% in 2023 to 37.7% in 2024, and further to 51.6% by 2025 [4] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately CNY 3.365 billion, CNY 4.012 billion, and CNY 3.241 billion, respectively [5] - The net profit after tax for the same periods was approximately CNY 580 million, CNY 605 million, and CNY 591 million [5] - Gross margins improved from 68.3% in 2023 to 75.3% in 2025 [6] Industry Overview - Cardiovascular diseases (CVD), chronic kidney disease (CKD), and metabolic disorders represent a significant burden on global public health, with the prevalence of cardiovascular-renal-metabolic syndrome reaching 88.9% among adults globally in 2024 [8][10] - The market for treatment drugs for cardiovascular-renal-metabolic syndrome is expected to grow from USD 328.9 billion in 2020 to USD 468.4 billion by 2024, with a compound annual growth rate (CAGR) of 9.2%, projected to reach USD 722.5 billion by 2029 and USD 947.5 billion by 2034 [10]